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and approximately 61 % of the dose was recovered in the 
carcass. Approximately 65 % of the dose was recovered 
in total, suggesting that approximately one-third of the 
leucine dose is oxidized to CO2. In conclusion, this study 
demonstrates endogenous production of HMB from leucine 
in adult rats, a standard preclinical model used to guide 
design of clinical trials in nutrition.
Keywords ADME · Leucine · Metabolism · HMB · 
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Introduction
The branched-chain amino acid leucine has been well 
studied for its ability to promote positive nitrogen bal-
ance as both a protein precursor and a signaling molecule 
in muscle of rats (Crozier et al. 2004), piglets (Boutry 
et al. 2013; Yin et al. 2010) and humans (Burd et al. 2012; 
Churchward-Venne et al. 2012; Li et al. 2011). Leucine has 
also been shown to decrease muscle protein breakdown 
in humans (Louard et al. 1990). Leucine serves as a sub-
strate for protein synthesis that occurs in the splanchnic 
bed and in skeletal muscle. Leucine not incorporated into 
splanchnic or skeletal muscle protein undergoes complex 
metabolism yielding several intermediate molecules and 
is ultimately oxidized (Fig. 1). The first intermediate mol-
ecule yielded by leucine metabolism, α-ketoisocaproic acid 
(KIC), is formed when leucine is reversibly transaminated 
within the muscle by mitochondrial branched-chain amino 
transferase (mBCAT). A proportion of KIC is a substrate 
for branched-chain alpha-keto acid dehydrogenase com-
plex (BCKDC), which irreversibly and oxidatively decar-
boxylates KIC to form isovaleryl-CoA. Alternatively, a 
fraction of KIC is decarboxylated and reduced in liver to 
Abstract Leucine is an essential branched-chain amino 
acid that acts as a substrate for protein synthesis and as a 
signaling molecule. Leucine not incorporated into muscle 
protein is ultimately oxidized through intermediates such 
as β-hydroxy-β-methylbutyrate (HMB) which itself is 
reported to enhance muscle mass and function in rats and 
humans. HMB has been reported in the plasma follow-
ing oral leucine administration in sheep and pigs but not 
in Sprague–Dawley rats, the standard preclinical model. 
Therefore, we conducted radiolabeled absorption, dis-
tribution, metabolism and excretion (ADME) studies in 
rats using a low (3 mg/kg) or high dose (1,000 mg/kg) of 
14C-leucine. Blood, tissue, and urine samples were ana-
lyzed for 14C-leucine and its metabolites by HPLC–MS. 
Our results show for the first time that 14C-HMB appears in 
plasma and urine of rats following an oral dose of 14C-leu-
cine. 14C-leucine appears in plasma as 14C-α-ketoisocaproic 
acid (KIC) with a slower time course than 14C-HMB, a 
putative product of KIC. Further, two novel metabolites of 
leucine were detected in urine, N-acetyl leucine and glycyl 
leucine. Mass balance studies demonstrate that excretory 
routes accounted for no more than 0.9 % of the radiolabel 
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yield β-hydroxy-β-methylbutyrate (HMB), also known 
as β-hydroxyisovalerate (CAS 625-08-1). This reaction is 
catalyzed by ketoisocaproate dioxygenase (4-hydroxyphe-
nylpyruvate dioxygenase; 4-HPPD; EC 1.13.11.27; CAS 
9029-72-5) which has been detected in the livers of rats 
(Sabourin and Bieber 1982) and humans (Xu et al. 2000). 
In biotin-deficient (Mock et al. 2011) or valproate-treated 
(Luis et al. 2012) patients, HMB can also be formed from 
leucine by the “ESCH 1 pathway”, which involves dehy-
drogenation of isovaleryl-CoA to methylcrotonyl-CoA, and 
conversion of methylcrotonyl-CoA to 3-hydroxyisovaleryl-
CoA by short-chain enoyl-CoA hydratase (ESCH 1; EC 
4.2.1.17).
HMB is a metabolite of interest because it has been 
shown to have some of the anabolic and anti-catabolic 
effects of leucine on muscle cells, particularly in highly 
catabolic conditions such as experimentally induced cancer 
cachexia (Aversa et al. 2011; Smith et al. 2005), bed rest 
(Deutz et al. 2013), immobilization (Hao et al. 2011), and 
sepsis (Kovarik et al. 2010; Supinski et al. 2010). In the cat-
abolic state, HMB helps stimulate muscle protein synthesis 
and inhibit breakdown by reducing proteasome activity and 
expression of the 20S subunit of the proteasome (Smith 
et al. 2005), by inhibition of apoptosis (Hao et al. 2011), 
and by activation of satellite cells (Alway et al. 2013; 
Kornasio et al. 2009).
Leucine conversion to HMB has been documented in 
vivo in sheep and pigs (Van Koevering and Nissen 1992) 
and in humans with biotin deficiency (Mock et al. 2011) or 
treated with the drug valproate (Luis et al. 2012). However, 
the metabolic profile of leucine has not been detailed in a 
rat ADME model. We wanted to explore the absorption, 
distribution, metabolism, and excretion of leucine using a 
standard ADME model, the Sprague–Dawley rat. Our study 
with 14C-leucine indicates that conversion to HMB occurs 
in the rat and is quantifiable in both plasma and urine.
Methods
Materials
2-14C-l-leucine (55 mCi/mmol) was purchased from Amer-
ican Radiolabeled Chemicals, Inc. (St. Louis, MO) as a 2 % 
ethanol aqueous solution at 0.1 mCi/mL (Fig. 2). 3-14C-β-
hydroxy-β-methylbutyrate (HMB) standard was prepared 
by the Process Organic Chemistry Department (now part of 
Abbvie, Inc.). In brief, 2-14C-acetone (100 mCi at 55 mCi/
mmol, American Radiolabeled Chemicals) and ethyl bro-
moacetate were condensed in a Reformatsky reaction with 
a Zn–Ag couple. The product, 3-14C-HMB ethyl ester, was 
obtained in 46 % yield and 98 % radiochemical purity. It 
was saponified to give the 3-14C-HMB in 65 % yield and 
98 % radiochemical purity as an aqueous solution. A por-
tion of this solution was diluted with water to give the 
working solution at 1.0 mCi/mL, 98 % radiochemical 
purity, and 55 mCi/mmol.
Animals and experimental design
The studies were approved by the Abbott Laboratories (now 
Abbvie, Inc.) Institutional Animal Care and Use Committee 
(protocol #1111A0131). A total of twenty-nine 12-month-
old male Sprague–Dawley rats (Hilltop Lab Animals, Inc. 
Fig. 1  Metabolism of leucine in mammals. mBCAT mitochondrial 
branched-chain aminotransferase, BCKDC branched-chain ketoacid 
dehydrogenase complex, 4-HPPD 4-hydroxy-phenylpyruvatediox-
ygenase, ECSH1 short-chain enoyl-CoA hydratase. The first inter-
mediate molecule yielded by leucine metabolism, α-ketoisocaproic 
acid (KIC), is formed when leucine is reversibly transaminated 
within the muscle by mitochondrial branched-chain amino trans-
ferase (mBCAT). Alternatively, a fraction of KIC is decarboxylated 
and reduced in liver to yield β-hydroxy-β-methylbutyrate (HMB), 
also known as β-hydroxyisovalerate (CAS 625-08-1). This reaction 
is catalyzed by ketoisocaproate dioxygenase (4-hydroxyphenylpyru-
vate dioxygenase; 4-HPPD; EC 1.13.11.27; CAS 9029-72-5) which 
has been detected in the livers of rat (Sabourin and Bieber 1982) and 
humans. Under some conditions, HMB can also be formed from leu-
cine by the “ESCH 1 pathway”, which involves dehydrogenation of 
isovaleryl CoA to methylcrotonyl-CoA, and conversion of methyl-
crotonyl-CoA to 3-hydroxyisovaleryl-CoA by short-chain enoyl-CoA 
hydratase (ESCH 1; EC 4.2.1.17)
Fig. 2  Structure of 2-14C-leucine administered to rats and of 3-14C-




Scottsdale, PA) were used in these studies and were accli-
mated to the laboratory for 4 days before use. Rats were given 
ad libitum access to Harlan Teklad #2018 Rodent Chow and 
tap water except as noted below for overnight fasting. To min-
imize animal use, these studies utilized 2–3 rats per group, 
typical of drug absorption, distribution, metabolism, and 
excretion studies. Extensive previous experience indicates 
that this number is adequate to obtain reliable results (Aubert 
et al. 2012; Gao et al. 2014; Hakk et al. 2009).
Animals were dosed with 3 or 1,000 mg/kg 14C-leucine. 
For the 3 mg/kg dose, a solution of 14C-leucine and non-
radiolabeled leucine in 5 % dextrose in water containing 
1.6 % ethanol was used. This dose was used to for both 
intravenous and oral administration. The final concentra-
tion of this solution was 3 mg/mL and utilized a dose vol-
ume of 1.0 mL/kg with a target radioactivity of 50 μCi/rat. 
For the high-dose studies, a suspension of 14C-leucine and 
non-radiolabeled leucine (1,000 mg/kg total dose) was pre-
pared in a standard oral gavage vehicle, 0.25 % carboxym-
ethylcellulose containing 0.1 % Tween 80. This suspension 
was used in part due to the limited solubility of leucine at 
this higher concentration (120 mg/mL) and was different 
from the vehicle used for the 3 mg/kg dose because only 
an oral formulation was required. The dose volume for 
this dose was 8.3 mL/kg and the target radioactivity was 
100 μCi/rat. The purity of the formulation under conditions 
of administration for all dose groups was >97 %.
Mass balance study
For the mass balance studies, nine male 12-month-old sur-
gically modified rats weighing 593 ± 21 g (mean ± SEM) 
were used. Rats had cannulas inserted into the bile duct and 
duodenum as well as a catheter inserted into the femoral 
artery by Hilltop Lab Animals, Inc., Scottsdale, PA. For 
this study, the rats were housed individually in metabo-
lism cages (up to 2 days). Rats were fasted overnight and 
food was returned 4 h post dose. On the day of dosing, 
the biliary and duodenal cannulas were disconnected and 
a solution of taurocholic acid (27.8 mg/mL) was infused 
through the duodenal cannula. Groups of three rats each 
received a single 3 mg/kg intravenous dose of 14C-leucine 
via the penile vein, a 3 mg/kg oral dose of 14C-leucine, or a 
1,000 mg/kg oral dose of 14C-leucine administered by gav-
age. Bile, urine, and feces were collected. The cages were 
washed at the end of study (48 h post dose) with a small 
amount of 70 % ethanol and the cage wash was collected 
for determination of total radioactivity.
Tissue distribution study
For the tissue distribution study, twenty male 12-month-old 
Sprague–Dawley rats, weighing 633 ± 11 g (mean ± SEM) 
were fasted overnight before being given a 3 or 1,000 mg/
kg (n = 10 per group) oral dose of 14C-leucine prepared as 
described above. Subgroups of two rats each were eutha-
nized by 95 % CO2–5 % O2 at 0.5, 1, 2, 4 and 24 h for col-
lection of blood and selected tissues (plasma, kidney, liver, 
lung, adipose, muscle, skin, small intestine and stomach). 
Blood samples were withdrawn via cardiac puncture into 
EDTA tubes. The plasma samples were obtained by cen-
trifugation of the blood samples.
General methods
Determination of total radioactivity
Total radioactivity in plasma, bile, urine and cage wash was 
determined directly by liquid scintillation counting (LSC) 
using a Model 3100TR Quanta Smart Liquid Scintillation 
Counter (Packard Instrument Company). Feces and tissues 
were homogenized in 70 % ethanol. Duplicated aliquots 
of fecal and liver homogenates were combusted in a Tri-
Carb® (Packard) Model 307 Sample Oxidizer), followed 
by LSC. Duplicate aliquots of all other tissue homogenates 
were solubilized in 1N sodium hydroxide at 40 °C, fol-
lowed by LSC. Carcass, including gastrointestinal tract and 
its contents, was weighed and submerged in KOH (10N) 
overnight on a shaker at low speed. The homogenate was 
weighed and aliquots were combusted as described above. 
Total radioactivity was calculated using estimates of total 
tissue weight (Caster et al. 1956; Davies and Morris 1993).
Sample preparation for metabolite identification 
and profiling
Radioactive materials in plasma were extracted by adding 
10 mL of acetonitrile to 1 mL of plasma, followed by vor-
tex mixing and centrifugation. An acetonitrile–methanol 
mixture (10 mL, 1/1, v/v) was used to extract the remain-
ing non-precipitable radioactive material from the protein 
pellet. The resulting pellet was then dissolved in 5 mL of 
1N sodium hydroxide and incubated for overnight at 60 °C. 
Radioactivity was assessed at each step of the extraction 
process by LSC.
Analytical methods
Radiolabeled components in urine and plasma samples 
were profiled following separation by HPLC and detec-
tion by an on-line radio flow detector (all samples) and in 
parallel with a mass spectrometer (Thermo LTQ Orbitrap) 
for representative samples. The HPLC system consisted of 
a Thermo Accela 1,250 pump and Thermo Accela autosa-
mpler connected to an IN/US β-Ram Model 5 flow scin-
tillation detector equipped with a 500 µL cell. For plasma 
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samples, radioactive profiles were obtained using HPLC 
fraction collection into Deepwell Luma Plate™-96; the 
radioactivity was counted by Perkin Elmer Microplate 
Scintillation Luminescence Counter Topcount NXT.
For plasma samples from rats following the 3 mg/kg 
dose, the elution of metabolites for negative ion mass spec-
trometry was achieved at room temperature on a Thermo 
Syncronis HILIC, 5 µm, 150 × 4.6 mm column equili-
brated with 10 % solvent A (ammonium acetate 10 mM) 
and 90 % solvent B (acetonitrile) at a flow rate of 1.0 mL/
min. After 3 min, a linear gradient was run to 40 % solvent 
A over 14 min and maintained for 2 min. For plasma sam-
ples from rats following the 1,000 mg/kg dose and urine 
samples, the elution of metabolites for further separation 
of leucine and HMB was achieved at room temperature on 
the same column equilibrated with 5 % solvent A and 95 % 
solvent B at a flow rate of 1.0 mL/min. After 5 min, a lin-
ear gradient was run to 20 % solvent A over 19 min, fol-
lowed by a linear gradient to 50 % solvent A over 2 min 
and maintained for 6 min.
Results
Plasma measures
Orally administered 14C-leucine appeared in the circula-
tion within 30 min of the gavage and remained detectable 
for the 24 h time course of the study (Fig. 3). The fate of 
14C-leucine in plasma following oral dosing of 1,000 mg/kg 
was investigated by determining the proportion of plasma 
radioactivity soluble in acetonitrile (ACN). The ACN-insol-
uble fraction is an estimate of 14C-leucine incorporation 
into plasma protein. Nearly 20 % of plasma 14C was found 
in the ACN-insoluble fraction 30 min post gavage increas-
ing to 60 % by 2 h and to 80 % at 24 h (Fig. 3).
Each ACN-soluble 14C-metabolite demonstrated a char-
acteristic time course of appearance in plasma (Fig. 3). 
While 14C-leucine and 14C-HMB peaked 1 h after oral 
dosing, 14C-KIC did not appear until 1 h post dosing, and 
climbed steadily thereafter. The KIC:leucine ratio in plasma 
ranged from 0 at 30 min to 0.66 at 4 h after the gavage.
The dose of 14C-leucine strongly affected metabolite 
profile in plasma and urine. At 1 h following oral dosing 
of 14C-leucine at 1,000 mg/kg, 73.1 % of the ACN-soluble 
radioactivity was recovered from plasma as 14C-leucine 
and 3.1 % as 14C-HMB (Fig. 4, panel B). In contrast, 
when 14C-leucine was administered orally at 3 mg/kg, 
96.3 % of 14C was recovered as 14C-leucine (Fig. 4, panel 
A). No peak was detected as 14C-HMB in plasma at this 
dose, even though spike experiments show that HMB could 
theoretically be recovered under the conditions employed 
(data not shown). In contrast, urine collected for 24 h fol-
lowing the oral 3 mg/kg dose contained 14C-labeled leu-
cine (2.8 %), HMB (7.2 %), KIC (15.0 %) along with other 
metabolites (Fig. 4, panel C). Following the 1,000 mg/kg 
dose, 10.7 % of radioactivity in urine appeared as leucine, 
4.9 % as HMB, and 53.0 % as KIC (Fig. 4, panel D) along 
with other metabolites. Spike experiments confirmed the 
recovery of HMB from urine under the HPLC conditions 
employed (data not shown).
Structural identification of four metabolites (M2, M3, 
M4, and M5) from the 24-h urine samples following the 
1,000 mg/kg oral dose of leucine was completed using 
LC–MS (Fig. 5). These metabolites were identified as the 
dipeptides leucyl-glycine (M2; 5.6 % of recovered radioac-
tivity) and N-acetyl-leucine (M4; 5.5 %), the ketone body 
acetoacetic acid (M3; 4.4 %), and the HMB precursor keto-
isocaproate (KIC, M5; 53.0 %).
Mass balance and tissue distribution
When 14C-leucine (3 mg/kg) was administered intrave-
nously, 61.4 % was recovered in the carcass 48 h post infu-
sion. No more than 0.9 % of the radioactivity was found in 
the cage, bile, urine, or feces, respectively. Both the pattern 
and total percent 14C recovery was similar when 14C-leu-
cine was given orally at either 3 or 1,000 mg/kg and was 
similar to that following the 3 mg/kg intravenous dose.
The time course of tissue distribution of 14C varied by 
dose and by organ (Fig. 6). By total size, skin, skeletal 
muscle, and liver were the primary targets of 14C disposi-
tion 24 h post dose with each tissue containing about 10 % 
of the 3 mg/kg dose or 5 % of the 1,000 mg/kg dose. In 
these experiments, time points were in duplicate. The figure 
demonstrates the similarity of the two separate animals for 
each time point throughout the time course of this study.



































Fig. 3  Distribution of 14C among leucine metabolites in plasma after 
oral administration of a bolus of 14C-leucine (1,000 mg/kg). Bar 
height is mean of total radioactivity measured in plasma from two 
rats. Individual data from each rat are presented numerically on top 
of each bar. Pooled plasma from each rat pair was fractionated with 
acetonitrile (ACN) and the percentage of radioactivity in each frac-





The rat ADME model is widely used to predict meta-
bolic products of drugs in humans. Demonstrating that 
the metabolic products of an amino acid are similar in the 
rat ADME model to those in human help establish the rat 
as a valid model for more complex studies. Furthermore, 
accompanying mass balance studies in rat also indicate 
the tissue sites associated with metabolism and eventual 
fate of the radiolabeled molecule. This series of ADME 
studies uses the rat model to demonstrate for the first 
time that the essential branched-chain amino acid, leu-
cine, appears in plasma and urine of rats as the metabo-
lite 14C-HMB following a dose of 14C-leucine. The stud-
ies also show for the first time that 14C-leucine appears 
in plasma as 14C-keto-isocaproic acid with a slower time 
course than 14C-HMB, its putative product. Further, two 
novel products of leucine were detected in urine, suggest-
ing additional pathways of leucine metabolism. Interest-
ingly, 2–24 h post dose the majority of circulating 14C 
in the plasma was found in the protein-bound form. The 
primary organs containing 14C at 24 h post dose were 
muscle, liver, and skin; each contained about 5–10 % of 
the total 14C dose. This study concurs with the previous 
literature showing that a substantial proportion of admin-
istered leucine is oxidized within a few hours (Costelli 
et al. 1995; White and Brooks, 1981). We found that 
when a bolus dose of 14C-leucine is orally administered 
to rats, about 35 % is lost from the body after 24 h, sug-
gesting that about one-third of the dose is oxidized to 
CO2.
A surprisingly high proportion of orally admin-
istered leucine was retained in plasma even 24 h after 
administration. This may be partially explained by the 
observation that over time, 14C-leucine (ACN soluble) 
appeared to be incorporated into plasma protein (ACN 
precipitable). This is consistent with previous observa-
tions that a flooding dose of radiolabeled phenylalanine 
is incorporated into plasma protein (Papet et al. 2003). 
Also consistent with the current study, other investiga-
tors have found that U-14C-leucine is rapidly incorpo-
rated into the TCA-insoluble fraction of plasma after 
intraperitoneal administration in rats (Casati et al. 1979). 
Therefore, it is possible that a large proportion of the 
14C-leucine administered may be incorporated into the 
























Fig. 4  Representative radiochromatograms showing the metabolite 
profile in plasma (a, b) and urine (c, d). Values represent concentra-
tion after an oral dose of 14C-leucine at 3 mg/kg (a, c) and 1,000 mg/
kg (b, d). Plasma values were collected 1 h post dose, while urine 
values were derived from urine collected for 24 h post dose. Slightly 
different chromatographic conditions were used for the two doses in 
plasma; validation experiments showing the recovery of spiked leu-
cine and HMB were performed and confirmed identity of the peaks in 
the figures (data not shown)
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the 14C-leucine to remain in the circulation since the 
albumin turnover rate is 62.8 %/day in adult rats (Papet 
et al. 2003).
After the 1,000 mg/kg dose, 14C-HMB appeared in 
plasma slightly in advance of its putative precursor, 
14C-KIC. Previous investigators have documented the 

















































Fig. 6  Distribution of 14C-leucine among tissues in rats following bolus oral administration of 14C-leucine. Each time point represents the per-
centage of dose administered to an individual rat. There are two bars per time point to represent the individual rats from each time point












































Fig. 5  Mass-spectrometric identification of leucine metabolites in urine following a single oral administration of 14C-leucine (1,000 mg/kg)
923β-Hydroxy-β-methylbutyrate in rats
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conversion of 14C-leucine to 14C-HMB in sheep and pigs 
(Van Koevering and Nissen 1992), findings we confirm 
here in a standard preclinical model. 14C-KIC appeared in 
plasma at minute concentrations in the first 2 h after the 
gavage. By 4 h after the gavage, the ratio of KIC: leucine 
is about 0.66, similar to that reported by others after an 
intravenous infusion of 1-14C-leucine (Laurent et al. 1984). 
Interestingly, in our study, the ratio of KIC:leucine derived 
from a radiolabeled dose is much higher than the ratio 
(~17 %) of unlabeled molecules reported in the plasma of 
both fed and starved rats (Hutson and Harper 1981).
The low dose (3 mg/kg body weight) of 14C-leucine was 
chosen to allow comparison of metabolism after oral and IV 
administration. The high dose (1,000 mg/kg body weight) 
was chosen to maximize the probability of detecting minor 
metabolites of leucine. At the 3 mg/kg dose, leucine was the 
major radiolabeled molecule identified in plasma (96.3 %) 
and no HMB was detected. However, at this dose, the con-
version of leucine to HMB did occur because HMB was 
identified in the “cumulative” urine collected for 24 h after 
the dose. In contrast, when 14C-leucine was administered at 
1,000 mg/kg, over a quarter of the plasma 14C was identi-
fied as HMB or other metabolites 1 h post gavage. Further 
examination of the differential response at these two doses 
demonstrated slightly different patterns of metabolism. In 
both plasma and urine, the higher dose allowed detection of 
a greater number of metabolites than the lower dose.
Independent of dose, when 14C-leucine was adminis-
tered either intravenously (IV) or orally, only a small frac-
tion of the 14C was recovered from the typical excretion 
routes of bile, urine (including cage wash) and feces (<5 % 
total). Because the amount of 14C was very low in the feces 
it is likely that the vast majority of the dose was absorbed. 
Our data demonstrate that approximately 60–65 % of the 
dose was recovered in the carcass 48 h post dose leaving 
the fate of the remaining approximately 35–40 % undeter-
mined. Previous investigators have found that about 8 % of 
an IV dose of 1-14C-leucine is oxidized to CO2 by 100 g 
rats over a 2-h period (Costelli et al. 1995). It is possible 
that over 48 h, as much as 35 % of orally administered leu-
cine could be lost to complete oxidation to CO2.
The major tissues were quantitated for 14C at various 
times up to 24 h post 3 or 1,000 mg/kg oral 14C-leucine 
dose. Regardless of the dose or time following dose, the tis-
sues with the highest 14C concentrations were liver, mus-
cle and skin. Previous investigators have also found that 
14C-leucine and its metabolic products accumulate in liver 
and muscle after oral administration of 14C-leucine (Lemon 
et al. 1982; Vazquez et al. 1986).
As would likely be expected, there was little 14C in the 
adipose tissue while the lung and kidney demonstrated 
high per gram concentrations that represented only a small 
fraction of the total dose when organ size was taken into 
account. The heart tissue demonstrated higher uptake of 
the radiolabel than the skeletal muscle on a per gram basis. 
However, given their relative contribution to the total body 
weight, skeletal muscle content of 14C far exceeded radiola-
bel in heart. Both muscle and skin were among the lowest 
concentrations of radioactivity on a per gram tissue basis 
but accumulated a similar fraction of the total radiolabel as 
liver. Other investigators have found that even 20 days after 
the oral dose of radiolabeled leucine, 48 % of the dose was 
retained, with 3 % in the liver and 8 % in skin (Neale and 
Waterlow 1974).
In summary, this study has demonstrated that a por-
tion of an oral dose of leucine is converted to HMB in the 
rat, that HMB may be detectable in urine even when it is 
not detectable in plasma, and that it appears in plasma in 
advance of its putative precursor, 14C-KIC. A possible 
explanation for these observations is that both steps of leu-
cine conversion to HMB may occur in some tissues, for 
instance, kidney. 4-HPPD, the enzyme that converts KIC to 
HMB, has been found in both liver and kidney as well as 
in neurons (Neve et al. 2003) and skeletal muscle (Wilkin-
son et al. 2013). Consequently, local tissue concentrations 
of HMB may be higher than those measured in plasma. 
Changes in 4-HPPD activity in physiological states such as 
aging, cachexia, and diabetes may affect the relative avail-
ability of HMB in unsupplemented individuals and should 
be explored.
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